STAT1 and cryohydrocytosis: We have previously shown that, in CHC patients undergoing antiviral therapy with pegIFN/ribavirin (the standard treatment for CHC before the advent of direct‐acting antivirals15), Tregs decline in vivo as early as after 2 days from therapy starting, in association with increased STAT1 phosphorylation.16